Monitoring and management for advanced non-alcoholic fatty liver disease, currently in research and development on the CyberLiver platform.
Obesity is a major cause of chronic liver disease and, with alcohol, accounts for the majority of non-viral cases. In advanced NAFLD, simply controlling fat is not enough.
Managing it means addressing a whole host of risk factors together, including loss of muscle mass and endurance. SteatoCare is our platform configuration for personalised monitoring and management of advanced NAFLD.
SteatoCare is in the R&D stage. We expect to bring the same platform approach, AI-driven monitoring within a managed clinical service, to advanced NAFLD. Talk to us if you'd like to be involved.